Novo Nordisk Faces Significant Stock Drop Following Obesity Drug Trial Disappointment

Novo Nordisk's stock dropped 18% after a phase three trial for its CagriSema weight loss drug yielded results below expectations. The drug, combining semaglutide and Cagrilintide, ...